Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6347830 | 0.93 | DYRK1A (0.30) | DYRK1A | |
| SCHEMBL6358239 | 0.92 | DYRK1A (0.41) | DYRK1A | |
| SCHEMBL6347622 | 0.90 | TOP2A (0.33) | — | |
| SCHEMBL6349347 | 0.89 | KDM1A (0.33) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6346601 | 0.85 | HCRTR1 (0.30) | — | |
| SCHEMBL6349124 | 0.84 | PRMT5 (0.32) | — | |
| SCHEMBL6356916 | 0.83 | CYP3A4 (0.31) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6358948 | 0.83 | KDM1A (0.33) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6344992 | 0.83 | GABRA1 (0.34) | GABRA1GABRG2GABRB3 | |
| SCHEMBL6350770 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864259-B2 | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 2005-03-08 | — | — | US | claimed |
| EP-1395585-A1 | ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2004-03-10 | — | — | EP | claimed |
| US-20030114458-A1 | Antibacterial agents | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | claimed |
| WO-2002096908-A1 | ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-12-05 | — | — | WO | claimed |
| US-6864259-B2 | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 2005-03-08 | — | — | US | disclosed |
| US-20030114458-A1 | Antibacterial agents | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114458-A1 | Antibacterial agents | MRPL21, RPS6, RPS6KA1 | GABRA1 3931/4885GABRG2 4612/4885GABRB3 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.